AVB-001 is under clinical development by Avenge Bio and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVB-001 is under development for the treatment of metastatic peritoneal cancers, ovarian cancer, fallopian tube cancer, mesothelioma and lung cancers. The therapeutic candidate comprises allogeneic genetically engineered cells expressing interleukin-2 (IL-2) in the tumor environment. It is administered through intraperitoneal route.
Avenge Bio overview
Avenge Bio focuses on Cell-Generated Immunotherapies to eradicate solid tumors. Avenge Bio is headquartered in Natick, Massachusetts, the US.
For a complete picture of AVB-001’s drug-specific PTSR and LoA scores, buy the report here.